- Home
- CRNX
CRNX
Crinetics Pharmaceuticals Inc.
as 05-30-2025 4:00pm EST
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | 2018 |
| Target Price: | $75.00 | AVG Volume (30 days): | 942.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.10 - $62.53 | Next Earning Date: | 05-08-2025 |
| Revenue: | $760,000 | Revenue Growth: | -61.50% |
| Revenue Growth (this year): | 343.7% | Revenue Growth (next year): | 733.93% |
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Struthers Richard Scott | CRNX | President & CEO | Mar 19 '25 | Sell | $34.50 | 17,338 | $593,016.96 | 329,147 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Mar 19 '25 | Sell | $34.50 | 2,515 | $86,021.37 | 72,360 | |
| Betz Stephen F. | CRNX | Chief Scientific Officer | Mar 19 '25 | Sell | $34.50 | 5,770 | $197,352.96 | 108,588 | |
| Knight Jeff E. | CRNX | Chief Operating Officer | Mar 19 '25 | Sell | $34.50 | 7,162 | $244,963.80 | 87,852 |
Latest Crinetics Pharmaceuticals Inc. News
CRNX Breaking Stock News: Dive into CRNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
Simply Wall St.
10 days ago
Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation?
GlobeNewswire
16 days ago
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
GlobeNewswire
19 days ago
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
22 days ago
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ...
Insider Monkey
22 days ago
Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back?
Zacks
23 days ago
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
23 days ago
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Compare CRNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.